Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PMN
- Price
- 16.17
- Stock movement up
- +0.92 (6.03%)
- Company name
- ProMIS Neurosciences Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 34.81M
- Ent value
- 31.68M
- Price/Sales
- -
- Price/Book
- 3.79
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -32.41%
- 3 year return (CAGR)
- -48.73%
- 5 year return (CAGR)
- -71.13%
- 10 year return (CAGR)
- -53.75%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PMN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 3.79 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.15M |
| EPS (TTM) | -21.01 |
| FCF per share (TTM) | -19.51 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -35.40M |
| Net income (TTM) | -29.28M |
| EPS (TTM) | -21.01 |
| EPS (1y forward) | -10.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.40M |
| Net receivables | 86.06K |
| Total current assets | 21.46M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 21.46M |
| Accounts payable | 4.21M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 12.21M |
| Total liabilities | 12.27M |
| Shareholder's equity | 9.19M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.20M |
| Capital expenditures (TTM) | 11.00 |
| Free cash flow (TTM) | -27.20M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -318.73% |
| Return on Assets | -136.47% |
| Return on Invested Capital | -318.73% |
| Cash Return on Invested Capital | -296.02% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 15.65 |
| Daily high | 16.50 |
| Daily low | 15.57 |
| Daily Volume | 44K |
| All-time high | 56340.00 |
| 1y analyst estimate | 34.71 |
| Beta | -0.09 |
| EPS (TTM) | -21.01 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 6 Apr 2026 |
Downside potential
Loading...
Downside potential data
| PMN | S&P500 | |
| Current price drop from All-time high | -99.97% | -1.82% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 28 Nov 2025 | 9 Mar 2009 |
| Avg drop from high | -81.45% | -10.84% |
| Avg time to new high | 252 days | 12 days |
| Max time to new high | 2502 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
34.81M
Marketcap category
Small-cap
Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Employees
7
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page